Skip to content

Melatonin and Epilepsy

The Effect of Melatonin in patients with intractable epilepsy

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2015013117811N7
Enrollment
30
Registered
2015-02-11
Start date
2013-06-01
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

intractable epilepsy. Epilepsy

Interventions

melatonin 3 mg nightly for 2 months.
Treatment - Drugs
melatonin 3 mg nightly for 2 months

Sponsors

Arak University of Medical Sciences , Office of Vice Chancellor for Research
Lead Sponsor

Eligibility

Sex/Gender
All
Age
15 Years to 80 Years

Inclusion criteria

Inclusion criteria: inclusion criteria : age 15–80 years ; clinically definitive intractable epilepsy confirmed by a neurologist ; presented to the Neurology clinics at Arak city between June, 2013 and March 2014 ; normal clinical exam ;Treatment with at least three appropriate anti-epileptic drugs had failed to control seizures in all patients exclusion criteria : neurodegenerative disorders ; brain neoplasm ; chronic hematological , cardiac , hepatic, renal or thyroid disorder ; history of smoking and addiction to drugs or alcohol.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
The number of monthly seizure episodes. Timepoint: baseline and after 2 months. Method of measurement: patients self report.;Sleep quality. Timepoint: baseline and after 2 months. Method of measurement: PSQI questionaries.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShayan Amjadi

Students Research Committe , Medicine faculty , Aarak University of Medical Sciences

shayanamjadi@yahoo.com+98 86 3417 3502

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026